CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financial results, and provide business updates for the fourth quarter and full-year 2021 on Thursday, April 28, 2022. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. EST.
Conference call and webcast details
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and GSK today announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup period of a maximum of two years, the contract grants the German federal government access to CureVac’s manufacturing capacity until 2029, enabling rapid availability of 80 million mRNA-based vaccine doses during the remainder of the current pandemic or in future infectious disease outbreaks. By reserving this manufacturing capacity, the tender seeks to mitigate risks associated with potential supply bottlenecks in a pandemic situation. Under the contract, the federal government will pay CureVac and GSK an annual standby fee after successful completion of the setup period, which requires the companies to maintain manufacturing capacity at constant readiness. By ensuring the availability of manufacturing capacities in Germany, the arrangement will significantly contribute to strengthening pandemic preparedness.
AC Immune Reports Changes to Senior Management
Howard Donovan appointed Chief HR Officer, joins executive committee
Joerg Hornstein, CFO, will leave to pursue new role
Chris Roberts promoted to Vice President, Finance and appointed Interim CFO
Julian Snow promoted to Vice President, U.S. Finance & Corporate Development
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced senior management changes. Howard Donovan will join the Company as Chief HR Officer and be appointed to the Executive Committee. Joerg Hornstein, Chief Financial Officer, will leave in the second half to pursue a new opportunity. Christopher Roberts, Associate Vice President, Finance, was promoted to Vice President, Finance and appointed interim CFO. Julian Snow, Associate Vice President, Financial Reporting, was promoted to Vice President, U.S. Finance & Corporate Development.
Heidelberg Pharma to Present New Data on its Proprietary ATAC® Technology Platform at the AACR Annual Meeting 2022
Heidelberg Pharma AG announced today that it will present preclinical data on its proprietary Amanitin-based ATAC® technology at the American Association for Cancer Research (AACR) 2022 Annual Meeting. The meeting will take place in New Orleans, Louisiana, USA, from 8th – 13th April 2022.
Details of the poster presentation:
Amatoxin-based antibody-drug conjugates induce immunogenic cell death and improve the anti-tumor efficacy of immune checkpoint inhibitors in humanized mouse models
AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases
a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially enables accelerated development of targeted therapeutics and additional a-syn diagnostics
Another first for validated Morphomer® discovery technology platform in developing small molecules able to selectively target pathological human proteins
AC Immune pipeline includes a-syn diagnostic and multiple a-syn therapeutic candidates
AC Immune on track to deliver seven clinical data readouts in 2022
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, hosted leading research scientist and key opinion leader Dr. Oskar Hansson for a webinar focused on a-synuclein as a diagnostic and therapeutic target in neurodegenerative diseases. AC Immune and Dr Hansson reported at the recent AD/PD™ conference, data showing that AC Immune’s wholly owned a-syn PET tracer ACI-12589 was the first-ever radiotracer to distinguish multiple system atrophy (MSA) from other a-synucleinopathies, i.e. Parkinson’s disease (PD) and Lewy body dementia (LBD), and healthy volunteers.
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against COVID-19 variants and other pathogens.
Heidelberg Pharma Announces Financial Figures for Fiscal Year 2021 and Provides Business Update
• Start of clinical trial with HDP-101 in multiple myeloma
• Signing of strategic partnership with Huadong Medicine
• Successful financing activities
• Financial figures in line with adjusted forecast
• Conference call to be held on 24 March 2022 at 3:00 p.m. CET
Heidelberg Pharma AG today published its financial results and Annual Report for fiscal year 2021 (1 December 2020 – 30 November 2021) and its outlook for 2022.
COSMO ANNOUNCES FULL-YEAR RESULTS 2021; CONFIRMS BEATING GUIDANCE
Cosmo Pharmaceuticals N.V. (“Cosmo”) reports full-year 2021 results for the year ended 31 December 2021, confirms beating guidance, and, as previously announced, proposes a dividend of €0.95 per share at the next AGM on 27 May 2022.
Immatics Announces Full Year 2021 Financial Results and Corporate Update
Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2021.
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
Seven clinical data readouts expected in 2022
Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022
Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H2 2022
Initiation of ACI-24 anti-Abeta vaccine Phase 1b/2 trial in patients with Alzheimer’s disease (AD) and people living with Down syndrome (DS) expected in H1 2022
AD/PD™ Conference: ACI-12589 identified as a reliable and accurate PET tracer for alpha-synucleinopathies (e.g. MSA)
Strong financial position of CHF 198.2 million ensures the Company is fully financed through at least Q1 2024
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the year ended December 31, 2021, and provided a corporate update, highlighting progress in its broad pipeline of products to treat and diagnose neurodegenerative diseases.
dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz